US 11,865,169 B2
Vaccine composition against Chlamydiaceae infections
Philippe Verbeke, Paris (FR); and Colette Kanellopoulos, Versailles (FR)
Filed by CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); UNIVERSITE PARIS DIDEROT PARIS 7, Paris (FR); and INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR)
Filed on Dec. 15, 2021, as Appl. No. 17/552,256.
Application 17/552,256 is a continuation of application No. 16/884,649, filed on May 27, 2020, granted, now 11,229,691.
Application 16/884,649 is a continuation of application No. 15/747,489, granted, now 10,695,416, issued on Jun. 30, 2020, previously published as PCT/EP2016/068079, filed on Jul. 28, 2016.
Claims priority of application No. 1557211 (FR), filed on Jul. 28, 2015.
Prior Publication US 2022/0160861 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/118 (2006.01); A61P 31/04 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/118 (2013.01) [A61P 31/04 (2018.01); G01N 33/56927 (2013.01); A61K 2039/521 (2013.01); G01N 2800/26 (2013.01)] 12 Claims
 
1. A method of protecting against infections caused by Chlamydia bacteria selected from the group consisting of Chlamydia muridarum, Chlamydia pneumoniae, Chlamydia psitacci, Chlamydia abortus, Chlamydia felis, Chlamydia caviae, Chlamydia pecorum, Chlamydia suis and Chlamydia trachomatis, comprising:
administering to a subject a composition comprising an immunogenic dose of an inactivated β-lactam-treated form of Chlamydia bacteria selected from the group consisting of Chlamydia muridarum, Chlamydia pneumoniae, Chlamydia psitacci, Chlamydia abortus, Chlamydia felis, Chlamydia caviae, Chlamydia pecorum, Chlamydia suis and Chlamydia trachomatis,
wherein the inactivated β-lactam-treated form of Chlamydia bacteria has been previously inactivated by treating with a β-lactam.